Hadassah_BrainLabs_Overview
•
1 like•209 views
Hadassah BrainLabs conducts preclinical research on neurological and psychiatric diseases using various animal models and advanced technologies. Located at the Hadassah-Hebrew University Medical Center, it offers state-of-the-art facilities including specialized laboratories, imaging technologies, and behavioral testing equipment. Experienced scientists study conditions like Alzheimer's, Parkinson's, autism and more through behavioral analyses, biochemical assays, and other outcome measures. Researchers from academia and industry can access these resources and expertise to aid their projects.
Report
Share
Report
Share
Download to read offline
Recommended
Are physicians ready for using e-Learning in continuing medical education?
- The document outlines Arash Hadadgar's research plan to study whether physicians are ready to use e-Learning for continuing medical education using the Theory of Planned Behavior framework.
- A questionnaire was developed and administered to 72 general practitioners to understand their attitudes, subjective norms, and perceived behavioral control regarding e-Learning usage.
- Preliminary results found generally positive attitudes but some barriers related to e-Learning systems and technical skills. Further studies are planned to validate the questionnaire and model.
The Future of Research at KAMC
The document outlines King Abdullah Medical City's (KAMC) vision for research by 2030, which is to achieve international leadership in education and research. It discusses plans to build research infrastructure through strategic recruitment, logistics support, and alliance partnerships. It also details initiatives to promote research and evidence-based practice through education programs. Finally, it identifies key research directions including integrated basic and clinical studies, educational/health management research, and focus areas such as oncology, neuroscience, and mass gatherings health research.
Prescription Drug Monitoring Program | State of California - Department of Ju...
Controlled Substance Utilization Review and Evaluation System (CURES) CURES 2.0 Soft Launch and Phas...
Add Nova Berrini - Corretor Brahma
A empresa anunciou um novo produto que combina hardware e software para fornecer uma solução completa para clientes. O produto oferece recursos avançados de inteligência artificial e aprendizado de máquina para ajudar os usuários a automatizar tarefas complexas. Analistas esperam que o produto ajude a empresa a crescer em novos mercados e aumentar sua receita nos próximos anos.
522F11-LON-E
This document provides an agenda for the 16th Annual CEE Private Equity Forum taking place in London. The two-day forum will include presentations and panels on topics such as the macroeconomic outlook for CEE countries, institutional investor perspectives on private equity as an asset class, challenges for private equity sponsors, and implications of new regulations. Over 300 participants from leading private equity funds, investment banks, law firms, and other industry players are expected to attend.
REPOWER radio scripts
The document provides sample scripts for radio advertisements for REPOWER, a company that offers solar power systems combined with smart home technology. The scripts range from 10 to 60 seconds and emphasize how REPOWER gives customers clean solar energy outside their home plus smart home features inside for savings, comfort and control. They encourage listeners to get a free quote at the local REPOWER website.
Recommended
Are physicians ready for using e-Learning in continuing medical education?
- The document outlines Arash Hadadgar's research plan to study whether physicians are ready to use e-Learning for continuing medical education using the Theory of Planned Behavior framework.
- A questionnaire was developed and administered to 72 general practitioners to understand their attitudes, subjective norms, and perceived behavioral control regarding e-Learning usage.
- Preliminary results found generally positive attitudes but some barriers related to e-Learning systems and technical skills. Further studies are planned to validate the questionnaire and model.
The Future of Research at KAMC
The document outlines King Abdullah Medical City's (KAMC) vision for research by 2030, which is to achieve international leadership in education and research. It discusses plans to build research infrastructure through strategic recruitment, logistics support, and alliance partnerships. It also details initiatives to promote research and evidence-based practice through education programs. Finally, it identifies key research directions including integrated basic and clinical studies, educational/health management research, and focus areas such as oncology, neuroscience, and mass gatherings health research.
Prescription Drug Monitoring Program | State of California - Department of Ju...
Controlled Substance Utilization Review and Evaluation System (CURES) CURES 2.0 Soft Launch and Phas...
Add Nova Berrini - Corretor Brahma
A empresa anunciou um novo produto que combina hardware e software para fornecer uma solução completa para clientes. O produto oferece recursos avançados de inteligência artificial e aprendizado de máquina para ajudar os usuários a automatizar tarefas complexas. Analistas esperam que o produto ajude a empresa a crescer em novos mercados e aumentar sua receita nos próximos anos.
522F11-LON-E
This document provides an agenda for the 16th Annual CEE Private Equity Forum taking place in London. The two-day forum will include presentations and panels on topics such as the macroeconomic outlook for CEE countries, institutional investor perspectives on private equity as an asset class, challenges for private equity sponsors, and implications of new regulations. Over 300 participants from leading private equity funds, investment banks, law firms, and other industry players are expected to attend.
REPOWER radio scripts
The document provides sample scripts for radio advertisements for REPOWER, a company that offers solar power systems combined with smart home technology. The scripts range from 10 to 60 seconds and emphasize how REPOWER gives customers clean solar energy outside their home plus smart home features inside for savings, comfort and control. They encourage listeners to get a free quote at the local REPOWER website.
QPS Neuropharmacology
Our profound expertise in Neuroscience and two decades of experience in contract research result in a sustainable advantage for our customers. QPS offers you a sophisticated range of validated transgenic and non-transgenic in vivo and in vitro models to guarantee that your new chemical or biological compounds are profiled in depth.
Eko Med 22 budimirovic
1) The document discusses the research of Dr. Adriana Bora into biomarkers for neurological disorders like HIV-associated neurological disorders (HAND) and autism spectrum disorder (ASD) using "omics" tools.
2) Her current research at Johns Hopkins has led to the discovery of novel protein biomarkers for early diagnosis of HAND. She is investigating molecular pathways affected by HIV in the brain using bioinformatics.
3) Working with Dr. Dejan Budimirovic, she is exploring the role of neuropeptides in ASD metabolism and developing assays to detect signature brain peptides in cerebral spinal fluid as potential ASD biomarkers.
FREEDOM NeuroShield -Brain Health Report
Innowave Freedom Clearing House /freedom Nano users can have single-click access to Neuroshield™,
Neuroshield™ is a Clinical Decision Support Tool for Neurological Disorders, A comprehancive tool to
evealuate Qualitative and Quantitative conditions of the Human Brain. Neuroshield™ is a product from
“In-Med Prognostics“Is a company with leadership in, reliable and data-driven brain health diagnostic and
prognostic tools
Pacitane nanoparticles drug release for brain disorder
This document summarizes research on using nanoparticles to deliver drugs to the brain and treat brain disorders. It discusses how nanoparticles carrying drugs can be administered orally and pass through the gastrointestinal tract and bloodstream to reach the brain. Specifically, it describes an experiment where pacitane nanoparticles were prepared and tested as a potential delivery system for treating brain disorders like Parkinson's disease and schizophrenia. The nanoparticles were characterized and tested for drug release in vitro. The results showed 80% of the drug was released within 24 hours. The conclusion is that nanoparticle drug delivery could provide an effective therapy for brain disorders.
Eko med 23-ispr.
Dr. Adriana Bora is submitting a research proposal to the Society for Neuroscience for the Peter and Patricia Gruber International Research Award, supported by the Gruber Foundation. Her proposal focuses on developing novel clinical assays using functional peptidomics/metabolomics to better understand and monitor the different stages of HIV-associated neurological disorders in patients, even those receiving antiretroviral therapy. She has previously identified important glycoproteins and biomakers in cerebral spinal fluid that are involved in various pathways impacted by HIV in the brain. Her future research aims to identify alternative pathways and routes used by HIV to alter brain metabolism and cause impairment, which could lead to more personalized treatment approaches for HAND patients.
CV Yaron_Gruper 170420.doc
Yaron Gruper is a highly trained biotech professional seeking a new clinical research position combining scientific and management skills. He has over 15 years of experience managing clinical trials from startup to completion in medical devices and pharmaceuticals. His most recent role was Director of Clinical Studies at Theranica Bio-Electronics where he oversaw pivotal neurology studies. He is skilled in site management, data management, regulatory submissions, and publication.
CV TRAN CHUNG THUY
Tran Chung Thuy is a medical doctor seeking a position in medical affairs, medical science liaison, or product management. He has over 15 years of experience in clinical practice and the pharmaceutical industry, most recently as an MSL at Hoffmann-La Roche promoting hepatitis, anemia, rheumatoid arthritis, and transplantation products. He is proficient in English and Vietnamese and has a strong track record of building relationships with key opinion leaders and external stakeholders.
Neuro Psycad
NeuroPsyCAD is an AI-based platform that analyzes brain scans to provide early and accurate diagnoses of neuropsychiatric disorders like Alzheimer's and Parkinson's. By sending brain scans to NeuroPsyCAD, clinicians receive a report within hours comparing the scan to a patient database and indicating the most likely diagnosis and its probability. This allows for earlier treatment and management of diseases, slowing their progression and reducing healthcare costs compared to traditional diagnostic methods. NeuroPsyCAD has been shown to be over 50% more accurate than expert clinicians in identifying some conditions like Alzheimer's from brain scans alone.
Aadhar Hospital, Solapur
Aadhar Hospital is a psychiatric institution in Solapur, Maharashtra committed to providing quality and affordable psychiatric services. It was inaugurated in 2010 by eminent actor and former Head of Psychiatry at BJ Medical College Pune, Dr. Mohan Agashe. The hospital offers treatment for various psychiatric conditions like anxiety, depression, schizophrenia, and addictions. It has clinical and rehabilitation services as well as infrastructure facilities like rooms, activity halls, treatment rooms, labs, and 24/7 backup systems.
: Insights from Leading CNS Players
Insights from Leading CNS Players
By Michael Davitian and David Dopfel, PhD
This is the fourth and final installment of our ongoing 2022 CNS year in review. See below for our the other blogs in the series:
CNS Year in Review: Introduction and Large CNS Diseases
https://healthadvancesblog.com/2023/03/29/introduction-and-large-cns-diseases/
CNS Year in Review: Going Digital
https://healthadvancesblog.com/2023/04/06/cns-year-in-review-going-digital/
CNS Year in Review: Novel Modalities
https://healthadvancesblog.com/2023/04/13/cns-year-in-review-novel-modalities/
Johnson and Johnson (Janssen), Roche, Biogen, Novartis and AbbVie are the leading biopharma players in the CNS space, with collective CNS sales in excess of $30B and active pipelines spanning neurodegeneration, psychiatry, and neurodevelopmental disorders. We identified several key themes in observing these players’ activities, investments and stated priorities:
* Sustained interest in neurodegenerative diseases with high unmet needs despite challenging historical development track records. This is motivated by the large commercial opportunity as well as improving basic neuroscience to understand disease pathways and patient segments
* Growing emphasis on, and investments in, basic research to improve disease understanding, identify better targets and therapeutics, and leverage precision medicine approaches (e.g., Janssen, Novartis, AbbVie)
* Increasing interest in deal-making among larger players as a means of bolstering portfolios
In our final 2022 CNS year in review blog, we provide a brief summary of these companies’ CNS strategy, approach, and recent activities.
###
Michael Davitian is a Vice President in our biopharma practice, where he focuses on building the firm’s expertise within neurology and ophthalmology.
David Dopfel, PhD is a senior analyst and member of Health Advances’ neurology and ophthalmology committee.
NEU538_Newsletter Issue19 V4 Flipper
The National Health & Medical Research Council recently awarded prestigious 5-year fellowships to five out of six applicants from Neuroscience Research Australia (NeuRA). These fellowships are designed to support leading health researchers and were awarded to NeuRA researchers conducting impactful research programs. NeuRA has also established the NeuRA Discovery Fund to attract and develop young research leaders through 5-year awards and enhance the quality of life through preventing and curing brain diseases. Donations to the fund will support research into diseases like Alzheimer's, Parkinson's, and mental illnesses.
Insights from Leading CNS Players: V2
This is the fourth and final installment of our ongoing 2022 CNS year in review. See below for our the other blogs in the series:
CNS Year in Review: Introduction and Large CNS Diseases
https://healthadvancesblog.com/2023/03/29/introduction-and-large-cns-diseases/
CNS Year in Review: Going Digital
https://healthadvancesblog.com/2023/04/06/cns-year-in-review-going-digital/
CNS Year in Review: Novel Modalities
https://healthadvancesblog.com/2023/04/13/cns-year-in-review-novel-modalities/
Johnson and Johnson (Janssen), Roche, Biogen, Novartis and AbbVie are the leading biopharma players in the CNS space, with collective CNS sales in excess of $30B and active pipelines spanning neurodegeneration, psychiatry, and neurodevelopmental disorders. We identified several key themes in observing these players’ activities, investments and stated priorities:
Sustained interest in neurodegenerative diseases with high unmet needs despite challenging historical development track records. This is motivated by the large commercial opportunity as well as improving basic neuroscience to understand disease pathways and patient segments
Growing emphasis on, and investments in, basic research to improve disease understanding, identify better targets and therapeutics, and leverage precision medicine approaches (e.g., Janssen, Novartis, AbbVie)
Increasing interest in deal-making among larger players as a means of bolstering portfolios
In our final 2022 CNS year in review blog, we provide a brief summary of these companies’ CNS strategy, approach, and recent activities.
Michael Davitian is a Vice President in our biopharma practice, where he focuses on building the firm’s expertise within neurology and ophthalmology.
David Dopfel, PhD is a senior analyst and member of Health Advances’ neurology and ophthalmology committee.
Leroy Hood biomedical challenges at Skolkovo
This document discusses biomedical challenges at Skolkovo and outlines several questions around the types of science and partnerships that will be involved. It discusses whether the initiatives will include both non-profit and for-profit organizations, and how to attract existing companies and enable new company creation. It also questions whether the funds will compete with other Russian science programs and if academic science in Russia will be reformed to align with the Skolkovo initiative. Overall, the document explores how to structure the biomedical programs and partnerships at Skolkovo across non-profit and for-profit organizations.
High-Content Analysis & Phenotypic Screening Conference 2016
CHI’s Thirteenth Annual High-Content Analysis meeting, the premier event showcasing the latest advancements in HCA applications and technologies, returns to San Diego with a new program. Over the years we have observed the technology mature and its adoption spread into many areas of compound screening/evaluation and functional analysis. The High-Content Analysis meeting will focus on the next steps of technology development, including screening of 3D and physiologically relevant complex models, ultra-high resolution and high-throughput imaging, more advanced image analysis and data management, and new assays and applications. The co-located Second Annual Phenotypic Screening meeting will address the advantages of phenotypic screening vs. target-based screening, and focus on assay development, selection of physiologically relevant models and subsequent target identification, as well as case studies of phenotypic screens from leading pharma. Join the original High-Content Analysis event and get access to two tracks featuring a cutting-edge scientific agenda, expanded exhibit hall and technology showcases, and an offering of technology demonstrations and dinner courses.
Personalized medicine tools for clinical trials - kuchinke
Tools for personalised medicine in clinical trials. ---------
The implementation of clinical trials in personalized medicine is a different way of doing clinical research compared to the standard way of large clinical trials aiming for statistical significance. Personalized medicine uses a medical model that separates people into different groups with medical decisions, practices, drugs, interventions being tailored to the individual patient based on their predicted response. Basis for this approach is the progress of the study of the human genome and its variation over the last two decades. Especially advancement in automated DNA sequencing and PCR and the use of expressed sequence tags (ESTs), cDNAs, antisense molecules, small nterfering RNAs (siRNAs), full-length genes and their expression products and haplotypes.
But adoption of personalized medicine requires an active and flexible and highly integrated infrastructure, which allows joining of many different competences and technologies. We asked the question: can the tools developed for personalized medicine in the p-pedicine project be employed effectively in a clinical trials network to support personalised clinical trials. We conducted an analysis of tool integration and the evaluation tool usage requirements. Based on the survey results, the tendency for clinical trial network ECRIN is to use software as a service in the form as SaaS or ASP. ECRIN data centres will (probably) not install and employ p-medicine tools in one of their data centres. A robust business model for the provision of services and the implementation and employment of tools does not yet exist.
How can the personalized medicine infrastructure p-medicine and the clinical trials network ECRIN gain from each other to allow the conduct of personalized clinical trials?
We suggest a business model, in which personal medicine infrastructures and clinical trials networks exchange their services to gain jointly from each other. Therefore: an integration by reciprocal exchange of services may be the solution. Not only software as a service will be exchanged, but also knowledge, personnel and joint staff trainings.
Personalized medicine tools for clinical trials - Kuchinke
Tools for personalised medicine in clinical trials.
The implementation of clinical trials in personalized medicine is a different way of doing clinical research, compared to the standard way of large clinical trials aiming for statistical significance. Personalized medicine uses a medical model that separates people into different groups with medical decisions, practices, drugs, interventions being tailored to the individual patient based on their predicted response. Basis for this approach is the progress of the study of the human genome and its variation over the last two decades. Especially advancements in automated DNA sequencing, PCR technologies and the use of expressed sequence tags (ESTs), cDNAs, antisense molecules, small interfering RNAs (siRNAs).
But the adoption of personalized medicine requires an active and flexible and highly integrated infrastructure, which must allow the joining of many different competences and technologies. We asked the question: can the tools developed for personalized medicine in the p-pedicine project be employed effectively in a clinical trials network to support personalised clinical trials? We conducted an analysis of tool integration and the evaluation of tool usage requirements. Based on the survey results, the tendency for the clinical trial network ECRIN is to use software as a service in the form of SaaS or ASP. ECRIN data centres will (probably) not install and employ p-medicine tools in one of their data centres. A robust business model for the provision of services and the implementation and employment of tools does not yet exist.
How can the personalized medicine infrastructure p-medicine and the clinical trials network ECRIN gain from each other to allow the conduct of personalized clinical trials? We suggest a business model, in which personalized medicine infrastructures and clinical trials networks exchange their services to gain jointly from each other. An integration of networks by reciprocal exchange of services may be the solution. Not only software as a service will be exchanged, but also knowledge, personnel and staff trainings.
Henning Müller et Michael Schumacher pour la journée e-health 2013
The document summarizes the work of the eHealth unit at HES-SO in Sierre, Switzerland. It conducts applied research in eHealth with the goal of supporting the health domain by connecting data and interpreting multiple sources for reliable decision making. Some of its projects include developing tools for monitoring and managing gestational diabetes, extracting concepts from medical images for similar case retrieval, and creating an infrastructure to integrate complex patient data from multiple sources to simulate treatment outcomes.
Guna_Rajagopal_CV
This document provides biographical and employment details for Dr. GUNARETNAM RAJAGOPAL. It outlines his current role as Global Head of Computational Sciences at Janssen Pharma R&D and lists his previous employment history. It also provides details of his education background and areas of expertise including total informatics strategy, integrative genomics, translational informatics, computational/systems biology, and cyber-infrastructure development. Finally, it describes some of his current and previous research projects focused on drug discovery, big data analytics, and collaborations with academic and industry partners.
MedicalResearch.com: Medical Research Exclusive Interviews January 7 2014
MedicalResearch.com features exclusive interviews with medical researchers from major and specialty medical and health care journals and meetings.
Professional Cognitive Therpay Solutions for Neuro-impaired Conditions
This presentation provides an overview of HAPPYneuron PRO cognitive therapy platform for professionals and their patients.
The presentation was given at a conference dedicated to cognitive fitness - The Shaprbrains Summit - in Jan 2010.
More Related Content
Similar to Hadassah_BrainLabs_Overview
QPS Neuropharmacology
Our profound expertise in Neuroscience and two decades of experience in contract research result in a sustainable advantage for our customers. QPS offers you a sophisticated range of validated transgenic and non-transgenic in vivo and in vitro models to guarantee that your new chemical or biological compounds are profiled in depth.
Eko Med 22 budimirovic
1) The document discusses the research of Dr. Adriana Bora into biomarkers for neurological disorders like HIV-associated neurological disorders (HAND) and autism spectrum disorder (ASD) using "omics" tools.
2) Her current research at Johns Hopkins has led to the discovery of novel protein biomarkers for early diagnosis of HAND. She is investigating molecular pathways affected by HIV in the brain using bioinformatics.
3) Working with Dr. Dejan Budimirovic, she is exploring the role of neuropeptides in ASD metabolism and developing assays to detect signature brain peptides in cerebral spinal fluid as potential ASD biomarkers.
FREEDOM NeuroShield -Brain Health Report
Innowave Freedom Clearing House /freedom Nano users can have single-click access to Neuroshield™,
Neuroshield™ is a Clinical Decision Support Tool for Neurological Disorders, A comprehancive tool to
evealuate Qualitative and Quantitative conditions of the Human Brain. Neuroshield™ is a product from
“In-Med Prognostics“Is a company with leadership in, reliable and data-driven brain health diagnostic and
prognostic tools
Pacitane nanoparticles drug release for brain disorder
This document summarizes research on using nanoparticles to deliver drugs to the brain and treat brain disorders. It discusses how nanoparticles carrying drugs can be administered orally and pass through the gastrointestinal tract and bloodstream to reach the brain. Specifically, it describes an experiment where pacitane nanoparticles were prepared and tested as a potential delivery system for treating brain disorders like Parkinson's disease and schizophrenia. The nanoparticles were characterized and tested for drug release in vitro. The results showed 80% of the drug was released within 24 hours. The conclusion is that nanoparticle drug delivery could provide an effective therapy for brain disorders.
Eko med 23-ispr.
Dr. Adriana Bora is submitting a research proposal to the Society for Neuroscience for the Peter and Patricia Gruber International Research Award, supported by the Gruber Foundation. Her proposal focuses on developing novel clinical assays using functional peptidomics/metabolomics to better understand and monitor the different stages of HIV-associated neurological disorders in patients, even those receiving antiretroviral therapy. She has previously identified important glycoproteins and biomakers in cerebral spinal fluid that are involved in various pathways impacted by HIV in the brain. Her future research aims to identify alternative pathways and routes used by HIV to alter brain metabolism and cause impairment, which could lead to more personalized treatment approaches for HAND patients.
CV Yaron_Gruper 170420.doc
Yaron Gruper is a highly trained biotech professional seeking a new clinical research position combining scientific and management skills. He has over 15 years of experience managing clinical trials from startup to completion in medical devices and pharmaceuticals. His most recent role was Director of Clinical Studies at Theranica Bio-Electronics where he oversaw pivotal neurology studies. He is skilled in site management, data management, regulatory submissions, and publication.
CV TRAN CHUNG THUY
Tran Chung Thuy is a medical doctor seeking a position in medical affairs, medical science liaison, or product management. He has over 15 years of experience in clinical practice and the pharmaceutical industry, most recently as an MSL at Hoffmann-La Roche promoting hepatitis, anemia, rheumatoid arthritis, and transplantation products. He is proficient in English and Vietnamese and has a strong track record of building relationships with key opinion leaders and external stakeholders.
Neuro Psycad
NeuroPsyCAD is an AI-based platform that analyzes brain scans to provide early and accurate diagnoses of neuropsychiatric disorders like Alzheimer's and Parkinson's. By sending brain scans to NeuroPsyCAD, clinicians receive a report within hours comparing the scan to a patient database and indicating the most likely diagnosis and its probability. This allows for earlier treatment and management of diseases, slowing their progression and reducing healthcare costs compared to traditional diagnostic methods. NeuroPsyCAD has been shown to be over 50% more accurate than expert clinicians in identifying some conditions like Alzheimer's from brain scans alone.
Aadhar Hospital, Solapur
Aadhar Hospital is a psychiatric institution in Solapur, Maharashtra committed to providing quality and affordable psychiatric services. It was inaugurated in 2010 by eminent actor and former Head of Psychiatry at BJ Medical College Pune, Dr. Mohan Agashe. The hospital offers treatment for various psychiatric conditions like anxiety, depression, schizophrenia, and addictions. It has clinical and rehabilitation services as well as infrastructure facilities like rooms, activity halls, treatment rooms, labs, and 24/7 backup systems.
: Insights from Leading CNS Players
Insights from Leading CNS Players
By Michael Davitian and David Dopfel, PhD
This is the fourth and final installment of our ongoing 2022 CNS year in review. See below for our the other blogs in the series:
CNS Year in Review: Introduction and Large CNS Diseases
https://healthadvancesblog.com/2023/03/29/introduction-and-large-cns-diseases/
CNS Year in Review: Going Digital
https://healthadvancesblog.com/2023/04/06/cns-year-in-review-going-digital/
CNS Year in Review: Novel Modalities
https://healthadvancesblog.com/2023/04/13/cns-year-in-review-novel-modalities/
Johnson and Johnson (Janssen), Roche, Biogen, Novartis and AbbVie are the leading biopharma players in the CNS space, with collective CNS sales in excess of $30B and active pipelines spanning neurodegeneration, psychiatry, and neurodevelopmental disorders. We identified several key themes in observing these players’ activities, investments and stated priorities:
* Sustained interest in neurodegenerative diseases with high unmet needs despite challenging historical development track records. This is motivated by the large commercial opportunity as well as improving basic neuroscience to understand disease pathways and patient segments
* Growing emphasis on, and investments in, basic research to improve disease understanding, identify better targets and therapeutics, and leverage precision medicine approaches (e.g., Janssen, Novartis, AbbVie)
* Increasing interest in deal-making among larger players as a means of bolstering portfolios
In our final 2022 CNS year in review blog, we provide a brief summary of these companies’ CNS strategy, approach, and recent activities.
###
Michael Davitian is a Vice President in our biopharma practice, where he focuses on building the firm’s expertise within neurology and ophthalmology.
David Dopfel, PhD is a senior analyst and member of Health Advances’ neurology and ophthalmology committee.
NEU538_Newsletter Issue19 V4 Flipper
The National Health & Medical Research Council recently awarded prestigious 5-year fellowships to five out of six applicants from Neuroscience Research Australia (NeuRA). These fellowships are designed to support leading health researchers and were awarded to NeuRA researchers conducting impactful research programs. NeuRA has also established the NeuRA Discovery Fund to attract and develop young research leaders through 5-year awards and enhance the quality of life through preventing and curing brain diseases. Donations to the fund will support research into diseases like Alzheimer's, Parkinson's, and mental illnesses.
Insights from Leading CNS Players: V2
This is the fourth and final installment of our ongoing 2022 CNS year in review. See below for our the other blogs in the series:
CNS Year in Review: Introduction and Large CNS Diseases
https://healthadvancesblog.com/2023/03/29/introduction-and-large-cns-diseases/
CNS Year in Review: Going Digital
https://healthadvancesblog.com/2023/04/06/cns-year-in-review-going-digital/
CNS Year in Review: Novel Modalities
https://healthadvancesblog.com/2023/04/13/cns-year-in-review-novel-modalities/
Johnson and Johnson (Janssen), Roche, Biogen, Novartis and AbbVie are the leading biopharma players in the CNS space, with collective CNS sales in excess of $30B and active pipelines spanning neurodegeneration, psychiatry, and neurodevelopmental disorders. We identified several key themes in observing these players’ activities, investments and stated priorities:
Sustained interest in neurodegenerative diseases with high unmet needs despite challenging historical development track records. This is motivated by the large commercial opportunity as well as improving basic neuroscience to understand disease pathways and patient segments
Growing emphasis on, and investments in, basic research to improve disease understanding, identify better targets and therapeutics, and leverage precision medicine approaches (e.g., Janssen, Novartis, AbbVie)
Increasing interest in deal-making among larger players as a means of bolstering portfolios
In our final 2022 CNS year in review blog, we provide a brief summary of these companies’ CNS strategy, approach, and recent activities.
Michael Davitian is a Vice President in our biopharma practice, where he focuses on building the firm’s expertise within neurology and ophthalmology.
David Dopfel, PhD is a senior analyst and member of Health Advances’ neurology and ophthalmology committee.
Leroy Hood biomedical challenges at Skolkovo
This document discusses biomedical challenges at Skolkovo and outlines several questions around the types of science and partnerships that will be involved. It discusses whether the initiatives will include both non-profit and for-profit organizations, and how to attract existing companies and enable new company creation. It also questions whether the funds will compete with other Russian science programs and if academic science in Russia will be reformed to align with the Skolkovo initiative. Overall, the document explores how to structure the biomedical programs and partnerships at Skolkovo across non-profit and for-profit organizations.
High-Content Analysis & Phenotypic Screening Conference 2016
CHI’s Thirteenth Annual High-Content Analysis meeting, the premier event showcasing the latest advancements in HCA applications and technologies, returns to San Diego with a new program. Over the years we have observed the technology mature and its adoption spread into many areas of compound screening/evaluation and functional analysis. The High-Content Analysis meeting will focus on the next steps of technology development, including screening of 3D and physiologically relevant complex models, ultra-high resolution and high-throughput imaging, more advanced image analysis and data management, and new assays and applications. The co-located Second Annual Phenotypic Screening meeting will address the advantages of phenotypic screening vs. target-based screening, and focus on assay development, selection of physiologically relevant models and subsequent target identification, as well as case studies of phenotypic screens from leading pharma. Join the original High-Content Analysis event and get access to two tracks featuring a cutting-edge scientific agenda, expanded exhibit hall and technology showcases, and an offering of technology demonstrations and dinner courses.
Personalized medicine tools for clinical trials - kuchinke
Tools for personalised medicine in clinical trials. ---------
The implementation of clinical trials in personalized medicine is a different way of doing clinical research compared to the standard way of large clinical trials aiming for statistical significance. Personalized medicine uses a medical model that separates people into different groups with medical decisions, practices, drugs, interventions being tailored to the individual patient based on their predicted response. Basis for this approach is the progress of the study of the human genome and its variation over the last two decades. Especially advancement in automated DNA sequencing and PCR and the use of expressed sequence tags (ESTs), cDNAs, antisense molecules, small nterfering RNAs (siRNAs), full-length genes and their expression products and haplotypes.
But adoption of personalized medicine requires an active and flexible and highly integrated infrastructure, which allows joining of many different competences and technologies. We asked the question: can the tools developed for personalized medicine in the p-pedicine project be employed effectively in a clinical trials network to support personalised clinical trials. We conducted an analysis of tool integration and the evaluation tool usage requirements. Based on the survey results, the tendency for clinical trial network ECRIN is to use software as a service in the form as SaaS or ASP. ECRIN data centres will (probably) not install and employ p-medicine tools in one of their data centres. A robust business model for the provision of services and the implementation and employment of tools does not yet exist.
How can the personalized medicine infrastructure p-medicine and the clinical trials network ECRIN gain from each other to allow the conduct of personalized clinical trials?
We suggest a business model, in which personal medicine infrastructures and clinical trials networks exchange their services to gain jointly from each other. Therefore: an integration by reciprocal exchange of services may be the solution. Not only software as a service will be exchanged, but also knowledge, personnel and joint staff trainings.
Personalized medicine tools for clinical trials - Kuchinke
Tools for personalised medicine in clinical trials.
The implementation of clinical trials in personalized medicine is a different way of doing clinical research, compared to the standard way of large clinical trials aiming for statistical significance. Personalized medicine uses a medical model that separates people into different groups with medical decisions, practices, drugs, interventions being tailored to the individual patient based on their predicted response. Basis for this approach is the progress of the study of the human genome and its variation over the last two decades. Especially advancements in automated DNA sequencing, PCR technologies and the use of expressed sequence tags (ESTs), cDNAs, antisense molecules, small interfering RNAs (siRNAs).
But the adoption of personalized medicine requires an active and flexible and highly integrated infrastructure, which must allow the joining of many different competences and technologies. We asked the question: can the tools developed for personalized medicine in the p-pedicine project be employed effectively in a clinical trials network to support personalised clinical trials? We conducted an analysis of tool integration and the evaluation of tool usage requirements. Based on the survey results, the tendency for the clinical trial network ECRIN is to use software as a service in the form of SaaS or ASP. ECRIN data centres will (probably) not install and employ p-medicine tools in one of their data centres. A robust business model for the provision of services and the implementation and employment of tools does not yet exist.
How can the personalized medicine infrastructure p-medicine and the clinical trials network ECRIN gain from each other to allow the conduct of personalized clinical trials? We suggest a business model, in which personalized medicine infrastructures and clinical trials networks exchange their services to gain jointly from each other. An integration of networks by reciprocal exchange of services may be the solution. Not only software as a service will be exchanged, but also knowledge, personnel and staff trainings.
Henning Müller et Michael Schumacher pour la journée e-health 2013
The document summarizes the work of the eHealth unit at HES-SO in Sierre, Switzerland. It conducts applied research in eHealth with the goal of supporting the health domain by connecting data and interpreting multiple sources for reliable decision making. Some of its projects include developing tools for monitoring and managing gestational diabetes, extracting concepts from medical images for similar case retrieval, and creating an infrastructure to integrate complex patient data from multiple sources to simulate treatment outcomes.
Guna_Rajagopal_CV
This document provides biographical and employment details for Dr. GUNARETNAM RAJAGOPAL. It outlines his current role as Global Head of Computational Sciences at Janssen Pharma R&D and lists his previous employment history. It also provides details of his education background and areas of expertise including total informatics strategy, integrative genomics, translational informatics, computational/systems biology, and cyber-infrastructure development. Finally, it describes some of his current and previous research projects focused on drug discovery, big data analytics, and collaborations with academic and industry partners.
MedicalResearch.com: Medical Research Exclusive Interviews January 7 2014
MedicalResearch.com features exclusive interviews with medical researchers from major and specialty medical and health care journals and meetings.
Professional Cognitive Therpay Solutions for Neuro-impaired Conditions
This presentation provides an overview of HAPPYneuron PRO cognitive therapy platform for professionals and their patients.
The presentation was given at a conference dedicated to cognitive fitness - The Shaprbrains Summit - in Jan 2010.
Similar to Hadassah_BrainLabs_Overview (20)
Pacitane nanoparticles drug release for brain disorder
Pacitane nanoparticles drug release for brain disorder
High-Content Analysis & Phenotypic Screening Conference 2016
High-Content Analysis & Phenotypic Screening Conference 2016
Personalized medicine tools for clinical trials - kuchinke
Personalized medicine tools for clinical trials - kuchinke
Personalized medicine tools for clinical trials - Kuchinke
Personalized medicine tools for clinical trials - Kuchinke
Henning Müller et Michael Schumacher pour la journée e-health 2013
Henning Müller et Michael Schumacher pour la journée e-health 2013
MedicalResearch.com: Medical Research Exclusive Interviews January 7 2014
MedicalResearch.com: Medical Research Exclusive Interviews January 7 2014
Professional Cognitive Therpay Solutions for Neuro-impaired Conditions
Professional Cognitive Therpay Solutions for Neuro-impaired Conditions
Hadassah_BrainLabs_Overview
- 1. Hadassah BrainLabs builds on the expertise of scientists at Hadassah-Hebrew University Medical Center and provides guidance and service to researchers from academia and industry along with dedicated laboratories and core facilities. Knowledge Center for Research on Brain Diseases Located at Hadassah Campus
- 2. Hadassah BrainLabs offers the widest range of models (genetic or interventional) for neurological and psychiatric diseases, complemented by state of the art capabilities in histopathology and genomics Advanced brain imaging facilities such as MRI and Micro-PET are available SPF-certified facilities and state of the art equipment are used for behavioral analysis of motor, cognitive, emotional and social domains in rodent models
- 3. Alzheimer's disease Myasthenia gravis Anxiety Disorders Tauopathies Cerebrovascular diseases Autism Parkinson's disease Prion diseases Schizophrenia Amyotrophic lateral sclerosis Epilepsy Environmental Models Multiple sclerosis Depression Customized Models In addition to behavioral analyses and brain imaging, outcome measures include an extensive array of biochemical, immunological ,molecular and histological assays. Depending on the needs of the researcher and the project, disease models (genetic, pharmacological, surgical, infectious and environmental) are available, for:
- 4. Our approach to project design and management is carefully individualized Advice is provided on planning experiments including important clinical insights Large complex projects undertaken as well as focused research and specific outcome measures PROJECT FLOW AT HADASSAH BRAINLABS – MUCH MORE THAN A PRECLINICAL CRO
- 5. Director Prof. Bernard Lerer: Professor of Psychiatry; Director, Biological Psychiatry Laboratory; Hadassah – Hebrew University Medical Center Scientific Manager Prof. Hanna Rosenmann: Director, Laboratory of Neurology, Department of Neurology, Hadassah – Hebrew University Medical Center Associate Director Prof. Tamir Ben Hur: Professor of Neurology; Head, Department of Neurology and Division of Medical Neurosciences, Hadassah – Hebrew University Medical Center Hadassah BrainLabs Management OUR ADDED VALUE Part of a large, academic medical center Non-profit facility Accomplished physician scientists Experienced management team Strong clinical background Highly competitive pricing More about our scientists: http://brainlabs.org.il/about- us/scientists/
- 6. Contact Us For More Information Hadassah BrainLabs Hadassah - Hebrew University Medical Center Ein Karem, Jerusalem 91120, Israel Tel: 972-2-6776967 Email: brainlabs@hadassah.org.il Visit Our Website http://brainlabs.org.il/